Blood Cancer Journal · 2019 · 51 citations · 15 references
MedicinePharmacologyPharmacotherapyCancer PharmacologyChemotherapyClinical PharmacologyCombination Cancer TherapyCombination ChemotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyMultiple MyelomaToxicity ManagementMaximum Tolerated EffectMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentRefractory Multiple MyelomaRelapsed Multiple Myeloma
Abstract Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maximum tolerated dose (MTD) of the combination (CarPan) and assess safety and efficacy among RRMM patients. Thirty-two patients (median of 4 prior lines of therapy) were enrolled. The MTD was carfilzomib 36 mg/m 2 (on days 1, 2, 8, 9, 15, and 16) and panobinostat 20 mg (TIW, 3 weeks on/1 week off, every 28 days), administered until progression. At the MTD, the most common grade 3/4, treatment-related adverse events were thrombocytopenia (41%), fatigue (17%), and nausea/vomiting (12%). The objective response rate (ORR) and clinical benefit rate were 63% and 68%, respectively. Median progression-free survival (PFS) and overall survival (OS) for the entire population were 8 and 23 months, respectively. No differences in terms of ORR (55% vs. 57%), median PFS (months 8 vs. 7 months) and OS (24 vs. 22 months) were observed between bortezomib-sensitive and -refractory patients. CarPan proved to be a safe and effective steroid-sparing regimen in a heavily pre-treated population of MM patients. (Trial registered at ClinicalTrial.gov: NCT01549431)
15
International uniform response criteria for multiple myeloma
Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations
Medicine, Hematology, Oncology +12
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng, Louise Carlson, Delia Gutman et al. · Blood · 2006 · 1.1K citations · Full text
Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text